Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adapta-Arbo: Molnupiravir versus placebo for acute dengue and chikungunya
RBR-2j2zw3hPhase 1Recruiting
- Sponsor
- Universidade Federal de Minas Gerais
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in dengue fever and Chikungunya (CHIKV) comparing Molnupiravir with Placebo (2 arms). Started Mar 2024; status: recruiting.
02
Drugs
molnupiravir
03
Conditions
dengue feverChikungunya (CHIKV)
Beyond the preview
Go deeper on RBR-2j2zw3h.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-2j2zw3h.